The management for some departments are clearly inexperienced and have not been in charge of managing people in the past. My direct supervisor had limited experience at only one company prior to joining Esperion and has no experience in the subfunction he was overseeing. The worst part is, the other departments we interact with also are not great at their functions so they would not easily recognize my supervisor was not knowledegable on the topics he was speaking on.
To add something to Lilly and Novo positions: both are with risk or a straight nonsense. If one wants to have more manufacturing capacity on his own without CMO contracts, one buys an underutilized plant from one of other pharma giants. This was what Biomarin did buying a plant in Ireland from Pfizer for 1/5 (yes!) of what Pfizer spent to build it. This happened under the previous Biomarin CEO. Novo and Lilly try to outbid each other who spends more and looking greater.
Our esteemed colleague from Lilly applauds taking over Catalent by Novo. This was a wrong move, overpaying for quick access to manufacturing coming with all the negative baggage. No synergy between two organizations. One pays such money for a company with established products, good pipeline and promising IP.
The company will build new plants in the US. Maybe a good move until 2029 presidency. Comparing to Novo acquisition of Catalent, it is more risk predicting the market and competitive landscape down the road. Is Lilly strategy right? On surface yes, but in reality we doubt Lilly's strategic planning abilities.
Rare diseases are a good excuse to acquire small companies for little money. Due to not growing pipeline, a new plan for apparent growth is to acquire a few for millions each and flash a new expanding pipeline. Call this sustainability.
Not much real happening. Most activities come from speculative investors spreading rumors and moving stock price.
The positive news are followed by negative and the cycle repeats. Inside the company the new management does not displace the old quickly enough. No reason for this since the production is stagnant and new products are not coming and the old management is of low value. New management gave up on company to be MA candidate since it is not possible at current finances. Management may engineer a next layoff to move MA ahead. Those with higher salaries and long history with company will be targeted. Question how many of old management will go? There are some candidates already on the list. Buckle up. Investors will be happy.
